Speakers

Expand/Collapse

Christalyn Rhodes
Advisor
Eli Lilly

Day Two

Wednesday November 20 2019

3:30 pm | Therapeutic Applications of RNA Editing

Shizuka Uchida
Professor WSR
Aalborg University

Day Two

Wednesday November 20 2019

11:00 am | A-to-I RNA Editing in Cardiovascular Disease

Erez Levanon
Professor
Bar-Ilan University

Erez Levanon is a professor of biology at the faculty of life sciences, Bar-Ilan University; Israel, where he is the head of the genomic research lab, focusing mainly with the study of RNA editing. He received his PhD from Tel-Aviv University after graduating the Adi Lautman Interdisciplinary Program for Outstanding Students. Later he was a postdoctoral research follow at the genetics department of Harvard Medical School. Prior to that, he was a senior scientist in Compugen LTD. He has published over 80 manuscripts and won several awards and fellowships.

Day Two

Wednesday November 20 2019

9:00 am | Emergence of Novel A-to-I RNA Editing Sites

Nina Papavasiliou
University Professor and Division Head
German Cancer Research Center, Heidelberg, Germany
Visiting Professor
Rockefeller University, New York

I have a long-standing interest in processes that generate informational diversity within cells. This interest originally directed my lab's work to DNA mutation in the context of the adaptive immune response specifically to mechanisms that direct mutation to antibody genes in the germinal center. This process which depends on AID-mediated DNA deamination followed by error prone repair generates immunoglobulin sequence diversity and underlies affinity maturation of the antibody response. More recently my interest in molecular processes that generate informational diversity within cells has expanded to the field of epitranscriptomics where my lab has been a leader in the field of RNA editing and modification with a focus on the functional relevance of the resulting transcriptomic diversity in healthy tissue (e.g. innate immune cells) and in disease (in the context of cancer).  

Day Two

Wednesday November 20 2019

1:30 pm | How ADAR1 can drive Disease Progression by Acting Both as an RNA Editor of Specific Transcripts & as a DNA Mutator of their Cognate Genes

Dong Wei
Chief Executive Officer
Edigene

Day Two

Wednesday November 20 2019

9:30 am | LEAPER: A Novel Oligonucleotide-Based RNA Base Editing Therapy Delivered via Lipid Nanoparticles (LNP) or Adenoassociated Virus (AAV)

Alan Herbert
Founder & Head of Discovery
InsideOutBio

Alan Herbert identified the Zα domain of ADAR. He was able to show using Mendelian Genetics that  Zα loss of function mutations with diminished binding to the left-handed Z-DNA and Z-RNA double helical conformations map directly to type I interferonopathies, establishing a biological role for these left-handed structures. Dr Herbert also pioneered family-based Genome Wide Association Studies in human populations and identified an immunosuppressive molecule predictive of response to anti-PD-1 cancer therapeutics while at Merck & Co. He founded InsideOutBio in the fall of 2017.

Day One

Tuesday November 19 2019

5:00 pm | Chair’s Closing Remarks & End of Day One

8:50 am | Chair’s Opening Remarks

Day Two

Wednesday November 20 2019

3:30 pm | Chair’s Closing Remarks & End of Conference

8:55 am | Chair’s Opening Remarks

Yong Chang
Senior Vice President of Development
Korro Bio

Day Two

Wednesday November 20 2019

3:00 pm | Path to Translating Natural RNA Editing into New Possibilities for Patients; Non-Clinical & Clinical Considerations

Dimitrios G. Zisoulis
Head of RNA Biology & Drug Discovery
Locano Bio

Day One

Tuesday November 19 2019

12:15 pm | Panel Discussion: Chemical Modifications of RNA

11:30 am | Cas & Non-Cas Proteins for RNA Modulation: RNA Editing & Beyond

Silvestro G. Conticello
Professor
National Research Centre Italy

Day One

Tuesday November 19 2019

10:00 am | What We Can Learn from the RNA Editing of the SARS-CoV-2 Transcriptome

Polly Leilei Chen
Principle Investigator and Assistant Professor
National University of Singapore

Day One

Tuesday November 19 2019

12:15 pm | Panel Discussion: Chemical Modifications of RNA

Day Two

Wednesday November 20 2019

1:00 pm | RNA Editing in Cancer: Functional Consequences and Therapeutic Potentials

Bora Baysal
Professor - Anatomic Pathology
Roswell Park

Day One

Tuesday November 19 2019

9:30 am | C-to-U RNA Editing by APOBEC3A & APOBEC3G Cytidine Deaminases

David Rodman
Executive VP R&D
ProQR

David Rodman, MD is our Executive Vice President of Research & Development. David joined ProQR in 2017 having previously served in leadership roles with Novartis Institutes for Biomedical Research (NIBR), Vertex Pharmaceuticals, miRagen Therapeutics and Nivalis Therapeutics. Prior to moving to industry in 2005, David had a distinguished academic career, leading the Center for Genetic Lung Diseases at the University of Colorado and directing the Cystic Fibrosis Care, Teaching and Research efforts at the National Jewish Medical and Research Center in Denver, Colorado. During 12 years in industry, David has had global responsibility for driving innovation in the translation of cutting-edge science into transformational new therapies for rare diseases including CF, pulmonary fibrosis, pulmonary artery hypertension and severe immunologic and inflammatory diseases. At Vertex Pharmaceuticals he directed early- and late-stage CF clinical development programs including Kalydeco®, Orkambi® and VX-661. David received a BA in Economics from Haverford College in 1976, an MD from the University of Pennsylvania in 1980 and completed training in Internal Medicine, Pulmonary and Critical Care Medicine at the University of Colorado. He has served as an advisor to the National Institutes of Health, was elected to the American Society for Clinical Investigation and is a Fellow of the American Heart Association.

Adrian Briggs
Head of Technology Development
Shape Therapeutics

Day One

Tuesday November 19 2019

9:00 am | Engineering Therapeutic ADAR Editing Guide RNAs with Maximal Activity & Specificity

David Huss
Head of Research
Shape Therapeutics

Day Two

Wednesday November 20 2019

11:30 am | Novel AAV Capsid Engineering for Delivery of RNA-Targeted Payloads & Beyond: the ShapeTX AAVidTM Directed Evolution Platform

Eli Eisenberg
Professor
Tel Aviv University

Eli Eisenberg is a Professor of Physics and a member of the Sagol school of neuroscience at Tel Aviv University. Since 2002, he has been working on bioinformatic analyses of RNA expression data. In particular, he has developed computational approaches for detection, quantification and analysis of RNA editing, focusing on the most common type of RNA editing, adenosine-to-inosine editing. These methods were utilized to chart the editome of multiple species, study the genomic and transcriptomic characteristics governing the scope of editing in each species, and understanding the ways in which editing may have a functional impact on the cell and the whole organism, in health and disease.

Day One

Tuesday November 19 2019

2:00 pm | Global Quantification Exposes Most DNA & RNA Off-Target Activity by Base Editors is Non-Specific

Remi Buisson
Assistant Professor
University of California Irvine

Day Two

Wednesday November 20 2019

2:30 pm | Quantification of Ongoing APOBEC3A Activity in Tumor Cells by Monitoring RNA Editing at Hotspots

Thorsten Stafforst
Professor
University of Tuebingen

Thorsten is professor of Nucleic Acid Biochemistry at the Interfaculty Institute of Biochemistry at the University of Tuebingen. He studied chemistry in Göttingen and expanded to chemical biology and bio-engineering during his postdoc in Zürich. In 2011, he started his independent lab in Tübingen, supported by an ERC Consolidator Grant. Since 2016, he is permanent professor in Tübingen supported by a Heisenberg-Professur (DFG). His lab focusses  mainly on site-directed RNA editing strategies and their exploitation in life sciences and medicine.

Day One

Tuesday November 19 2019

2:30 pm | Harnessing Endogenous ADAR